Tiane Dai, MD, PhD
Investigator, The Lundquist Institute
Research DescriptionDr. Tiane Dai's experimental and clinical research focuses on all aspects of diabetic kidney disease, glomerulonephritis and peritoneal dialysis. She has discovered molecules in the urine that facilitate the identification of kidney disease early on. Her most recent research interest converges on treatment strategies for preventing peritoneal membrane functional decline in patients receiving peritoneal dialysis for their end stage renal disease.
Recent and/or Significant Publications
Ditsawanon P, Wu Q, Adler SG, Wang Y, LaPage J, Nayak A, Andalibi A, Aramwit P, and Dai T. Inflammatory Biomarker Pairs as Outcome Measures in Peritoneal Dialysis: A Pilot Study. Proceedings of UCLA Healthcare. 20, 2016.
Dai T, Wang Y, Nayak A, Nast CC, Quang L, LaPage J, Andalibi A, Adler SG.Janus kinase signaling activation mediates peritoneal inflammation and injury in vitro and in vivo in response to dialysate. Kidney Int. 2014; 86(6):1187-96.
Satirapoj B, Wang Y, Chamberlin MP, Dai T, LaPage J, Phillips L, Nast CC, Adler SG. Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. Nephrol Dial Transplant. 2012; 27(7):2702-11.
Satirapoj B, Bruhn KW, Nast CC, Wang Y, Dai T, Lapage J, Wu X, Natarajan R, Adler SG. Oxidized low-density lipoprotein antigen transport induces autoimmunity in the renal tubulointerstitium. Am J Nephrol. 2012; 35(6):520-30.
Patel-Chamberlin M, Wang Y, Satirapoj B, Phillips LM, Nast CC, Dai T, Watkins RA, Wu X, Natarajan R, Leng A, Ulanday K, Hirschberg RR, Lapage J, Nam EJ, Haq T, Adler SG. Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species. Kidney Int. 2011; 79(10):1138-48.